Ashish Ruhani
1.1K posts
@ashishruhani
Founder & CEO - WebApptics
H.C. Wainwright🏁 $TRVI Buy-$21 and said, "Potential Best-in-Class RCC Data, But it's Not Even $TRVI's Lead Indication." $GSK $MRK H.C. Wainwright additionally said, "We are initiating coverage of $TRVI stock with Buy rating and $21 price target. $TRVI is developing Haduvio for both refractory chronic cough (RCC) and Idiopathic Pulmonary Fibrosis chronic cough (IPF-CC). We view the company's RIVER Phase 2a data in RCC, released earlier this year, as compelling, and believe that $TRVI now has a meaningfully more derisked path to approval in RCC than the market gives the company credit for. While we believe $TRVI can generate $1B+ in revenue in RCC, the company's lead indication is IPF-CC, which is expected to readout Phase 2b data later this quarter, and in which we have seen promising data to date, and offering another $1B+ revenue opportunity for $TRVI, which the company could commercialize itself, given the orphan nature of that indication."
$TRVI Look for data drop Monday (June 2nd) or we will see it hit on the 16th (just my opinion). Thisnis the company's biggest data set yet and with good figured on the P2B results, a BP could very well swoop up Trevi in short order. Best in Class drug incoming for unmet needs.
